Regencell Bioscience Holdings, a Hong Kong-based biotech focused on Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders, experienced an extraordinary stock rally in 2025, peaking at an 82,000% gain before a rapid 74% decline. The surge was fueled primarily by retail investor speculation triggered by a 38-for-1 stock split, increasing liquidity and enabling a short squeeze. Despite having no FDA approvals, revenue, or licensing deals, the company's flagship herbal formulas targeting ADHD and autism attracted intense market enthusiasm. The extraordinary volatility prompted multiple trading halts as regulators responded to the frenzy reminiscent of prior meme-stock episodes. The episode underscores the risks of retail-driven speculative bubbles in biotech sectors with nascent products.